DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 93 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Negative impactCompany

Nectar Lifesciences Limited — Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company

NSE 1 hr ago·3 Oct 2026, 10:45 am

Nectar Lifesciences

Nectar Lifesciences Limited has informed stock exchanges about pending legal disputes or litigation that could impact the company. The company has stated that the outcome of these legal matters is uncertain and could have a material effect on its financial position or operations.

For investors, this development introduces a layer of risk. While the company has not disclosed the specific nature of the disputes, pending litigation can lead to financial liabilities or operational distractions. This news may cause short-term volatility in the stock price as market participants assess the potential severity of the legal issues.

Investors should monitor the company's future disclosures for updates on these cases. It is important to wait for clarity on the legal proceedings before making any investment decisions.

Affected stocks

Bearish1 stock

Nectar Lifesciences

NECLIFE Bearish

₹10.23

Bull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.

Key takeaways

Concerns Nectar Lifesciences (NECLIFE).
Category: Company.
AI reads the tone as negative (potentially bearish) for the stock.

Why it matters

A routine update for Nectar Lifesciences. The tone is negative — watch for downside reaction. Use the price and stock snapshot to gauge how the market is responding.

Summary & analysis by DocStoX. Full story at NSE.